Loading stock data…
Anika Therapeutics Inc. (ANIK)
$15.13+0.03 (+0.20%)
Market OpenUpdated 2:05 PM EDT
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Anika Therapeutics, Inc. in the Healthcare sector is trading at $15.13 with a market capitalization of $192M. Wall Street consensus targets $17.50 (2 analysts), implying a +15.7% move over the next 12 months. The stock is currently near its 52-week high of $16.24, remaining 28.8% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +15.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $29.61M↓ | $30.61M↑ | $27.82M↓ | $28.22M↑ | $26.17M |
| Gross Profit | $19.00M↓ | $19.18M↑ | $15.58M↑ | $14.36M↓ | $14.68M |
| Operating Income | -$5.49M↓ | $646,000↑ | -$3.23M↑ | -$4.18M↑ | -$4.28M |
| Net Income | -$5.06M↓ | $292,000↑ | -$2.33M↑ | -$3.97M↑ | -$4.87M |
Peer Comparison
JNJUNHPFE
Fundamentals
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Or...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$191.73M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.16
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-8.26%
Volume
Today's trading volume
36,081
Recent News
President of Anika Therapeutics Picks Up 51% More Stock
Investors who take an interest in Anika Therapeutics, Inc. ( NASDAQ:ANIK ) should definitely note that the President...
Anika Therapeutics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Anika Therapeutics, Inc.'s Q1 2026 earnings call
Anika Therapeutics Q1 Earnings Call Highlights
Anika Therapeutics (NASDAQ:ANIK) reported first-quarter 2026 results highlighting continued momentum in its commercial channel, progress in its hyaluronic acid (HA)-based product pipeline, and early benefits from operational changes aimed at improving profitability and scalability. Commercial chann
Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization
By Karen Roman Exec Edge sat down with Nadeem Moiz, Chief Executive Officer at Revance, to learn more about the company’s vision in aesthetics, skincare and therapeutics. Exec Edge: Tell us about Revance and the science-powered products within your portfolio across aesthetics, skincare and therapeutics. At Revance we believe that science based innovative products drive […]
Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference
Anika Therapeutics (NASDAQ:ANIK) CEO Steve Griffin outlined the company’s strategy, product portfolio, and growth priorities during a presentation at the Canaccord Genuity Musculoskeletal Conference, emphasizing a focus on top-line growth, a differentiated hyaluronic acid-based technology platform,